Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial. (2022)
Attributed to:
AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/s41467-022-34839-9
PubMed Identifier: 36435798
Publication URI: http://europepmc.org/abstract/MED/36435798
Type: Journal Article/Review
Volume: 13
Parent Publication: Nature communications
Issue: 1
ISSN: 2041-1723